Central European Cooperative Oncology Group

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Non-small-cell Lung Cancer, Medicine, Cancer Management +6

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

Giorgio V. Scagliotti, Thomas Brodowicz, Frances A. Shepherd et al. · Journal of Thoracic Oncology · 2010 · 252 citations · Full text

Treatment-by-histology Interaction Analyses, Medicine, Pathology +5

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 183 citations

Breast Oncology, Medicine, Pathology +7

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2020 · 130 citations · Full text

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

Sibylle Loibl, Tomáš Skácel, Valentina Nekljudova et al. · BMC Cancer · 2011 · 120 citations · Full text